-
METTL14–DHRS4-AS1 Axis in Ulcerative Colitis
2026-09-26
A 2024 study links METTL14-dependent m6A modification to DHRS4-AS1 expression and a miR-206/A3AR pathway in experimental ulcerative colitis. Cell and mouse findings suggest that this regulatory axis can influence inflammatory signaling, cell injury, and colonic damage, while leaving important questions about human disease and therapeutic relevance open.
-
High-Content Screening of Schistosome Stem Cells
2026-09-25
The study developed an image-based assay to quantify dividing somatic neoblasts in developmentally advanced Schistosoma mansoni schistosomula, addressing limitations of morphology- and motility-only screens. Screening a stem cell-focused compound collection produced prioritized candidates that impaired parasite development and stem cell proliferation, while also providing a platform for investigating parasite biology and anti-schistosomal leads.
-
Blue Light Disrupts Skin Barrier via EGFR/ERK/c-Jun
2026-09-25
A human and mouse study links repeated blue-light exposure to persistent skin-barrier impairment, including increased transepidermal water loss, reduced hydration, and epidermal thickening. Its central mechanistic contribution is implicating EGFR/ERK/c-Jun signaling in this response, while the findings also highlight exposure parameters and measurement approaches relevant to follow-up work.
-
Bovine Insulin for Stem-Cell Culture Workflows
2026-09-24
Use Bovine Insulin as a controlled metabolic supplement when testing how culture conditions shape dental pulp stem-cell growth—not as a proven anti-aging treatment. This workflow connects a recent Biodentine study to practical insulin dose controls, assay choices, and troubleshooting for more interpretable results.
-
Escitalopram: From Transporter Selectivity to Translation
2026-09-24
Escitalopram offers a precise entry point for studying serotonin transporter biology—but transporter selectivity alone cannot explain complex behavioral or clinical outcomes. This article connects its mechanistic profile with assay design and a clinical augmentation study to help translational researchers frame stronger, more interpretable experiments.
-
Gut Dysbiosis, STAT3 Signaling, and Prostate Cancer
2026-09-23
Zhong et al. connect antibiotic-associated gut dysbiosis with prostate tumor growth and docetaxel resistance through a gut-barrier–LPS–NF-κB–IL6–STAT3 pathway. Mouse experiments support a causal role for microbiota disruption, while patient data identify Proteobacteria as a candidate correlate of metastatic disease—not yet a validated clinical test.
-
ML385: Selective NRF2 Inhibitor for Research
2026-09-23
ML385 is a selective NRF2 inhibitor used to investigate NRF2 signaling pathway inhibition, oxidative stress modulation, and cancer therapeutic resistance. Its reported activity in A549 non-small cell lung cancer models and as a pathway-control reagent in osteoclast studies supports mechanistic research, but assay-specific potency and model-dependent responses must be verified experimentally.
-
Melatonin, Autophagy, and Hypertrophic Scar Fibrosis
2026-09-22
The reference study links melatonin’s anti-fibrotic activity in hypertrophic scar fibroblasts to MT2-associated suppression of PI3K/Akt/mTOR signaling and enhanced autophagy. Its combination of primary human cells, pharmacological pathway tests, transcriptomics, and a rabbit ear model provides a mechanistic framework for evaluating scar biology while highlighting the need to pair redox measurements with functional and signaling data.
-
Smoothened in Honeybee Olfaction: Study Insights
2026-09-22
Guo et al. characterize Smoothened (Smo) in Apis mellifera and connect antennal Smo activity with olfactory receptor expression, electroantennographic responses, and odor-guided behavior. The study provides an important insect sensory model for Hedgehog signaling while showing why pharmacological findings in bees should not be directly equated with vertebrate regenerative applications.
-
NF 449 in P2X1 Platelet Studies
2026-09-21
NF 449 is a high-potency purinergic receptor antagonist for separating ATP-driven P2X1 signaling from broader platelet responses. This workflow-oriented guide covers receptor assays, collagen-induced platelet aggregation, thrombus models, and practical troubleshooting for antithrombotic agent research.
-
Recombinant Mouse CD4, Tag Free Workflow
2026-09-21
Use Recombinant Mouse CD4, Tag Free as a defined reagent for binding, competition, and antibody-specificity assays that add immune context to placental necroptosis research. This workflow separates direct CD4 measurements from RIPK1–MLKL pathway readouts, helping researchers avoid overinterpreting a useful orthogonal assay as a disease surrogate.
-
PD0325901: MEK Inhibition Meets Genome Folding
2026-09-20
A translational strategy for using PD0325901 to connect pathway engagement, cancer-cell phenotypes, xenograft evidence, and emerging principles of genome organization without overstating cross-domain biology.
-
AY 9944 Dihydrochloride: DHCR7 Research Guide
2026-09-19
AY 9944 dihydrochloride is a selective DHCR7 inhibitor that drives 7-dehydrocholesterol accumulation by blocking its conversion to cholesterol. Product data report a 13 nM IC50 against recombinant human DHCR7, while 2026 genetic evidence links dhcr7 disruption to stronger antiviral resistance in grass carp.
-
Q-VD-OPh: Reliable Caspase Inhibition
2026-09-18
Learn how Q-VD-OPh (SKU A1901) can clarify caspase-dependent cell death, support post-cryopreservation viability studies, and improve interpretation of apoptosis assays. This scenario-based guide covers experimental controls, solvent handling, data interpretation, and practical product selection.
-
AY 9944 Dihydrochloride: Causal DHCR7 Assays
2026-09-18
AY 9944 dihydrochloride is a selective DHCR7 inhibitor for experimentally shifting sterol balance from cholesterol toward 7-dehydrocholesterol. This article develops a causal assay framework that connects biochemical inhibition with immune, membrane-raft, and emerging antiviral evidence while distinguishing chemical perturbation from permanent gene disruption.